

Figure 1: Aotearoa New Zealand Ministry of Health – Manatū Hauora guidelines for the testing of Lynch syndrome in newly diagnosed patients with colorectal cancer.




Table 1: Demographic variables.

| Characteristic | N | Overall, N=660 | Patients not completing IHC testing, N=107 | Patients completing IHC analysis, N=553 | p-value |
|------------------|-----|---------------------|--|---|---------|
| Gender | 660 | | | | >0.9 |
| F | | 303/660 (46%) | 49/107 (46%) | 254/553 (46%) | |
| M | | 357/660 (54%) | 58/107 (54%) | 299/553 (54%) | |
| Age | 660 | 72.00 [64.00–80.00] | 76.00 [65.00–85.50] | 72.00 [64.00–79.00] | 0.005 |
| Ethnicity | 660 | | | | 0.14 |
| NZ European | | 482/660 (73%) | 80/107 (75%) | 402/553 (73%) | |
| NZ Māori | | 91/660 (14%) | 19/107 (18%) | 72/553 (13%) | |
| Other | | 11/660 (1.7%) | 1/107 (0.9%) | 10/553 (1.8%) | |
| Other European | | 73/660 (11%) | 6/107 (5.6%) | 67/553 (12%) | |
| Pacific peoples | | 3/660 (0.5%) | 1/107 (0.9%) | 2/553 (0.4%) | |

Table 2: Clinicopathological variables.

| Characteristic | N | Overall, N=553 | Non-LS associated CRC, N=534 | LS associated CRC, N=4 | p-value |
|-------------------------------|-----|----------------|------------------------------|------------------------|---------|
| T stage | 450 | | | | 0.20 |
| T0 | | 6/450 (1.3%) | 6/447 (1.3%) | 0/3 (0%) | |
| T1 | | 48/450 (11%) | 48/447 (11%) | 0/3 (0%) | |
| T2 | | 71/450 (16%) | 69/447 (15%) | 2/3 (67%) | |
| T3 | | 238/450 (53%) | 237/447 (53%) | 1/3 (33%) | |
| T4 | | 87/450 (19%) | 87/447 (19%) | 0/3 (0%) | |
| Unknown | | 103 | 102 | 1 | |
| N stage | 450 | | | | >0.9 |
| N0 | | 273/450 (61%) | 271/448 (60%) | 2/2 (100%) | |
| N1 | | 114/450 (25%) | 114/448 (25%) | 0/2 (0%) | |
| N2 | | 61/450 (14%) | 61/448 (14%) | 0/2 (0%) | |
| N3 | | 2/450 (0.4%) | 2/448 (0.4%) | 0/2 (0%) | |
| Nx | | 103 | 101 | 2 | |
| Unknown | | | | | |
| Acuity | 535 | | | | >0.9 |
| Acute | | 80/535 (15%) | 80/531 (15%) | 0/4 (0%) | |
| Elective | | 455/535 (85%) | 451/531 (85%) | 4/4 (100%) | |
| Unknown | | 18 | 18 | 0 | |
| Tumour differentiation | 460 | | | | 0.11 |
| G1 | | 189/460 (41%) | 186/456 (41%) | 3/4 (75%) | |
| G2 | | 213/460 (46%) | 213/456 (47%) | 0/4 (0%) | |
| G3/4 | | 58/460 (13%) | 57/456 (12%) | 1/4 (25%) | |
| Unknown | | 93 | 93 | 0 | |

Figure 2: Flow chart of screening for Lynch syndrome (LS) by immunohistochemical staining for mismatch repair (MMR) proteins in patients with newly diagnosed colorectal cancer (CRC).

